Tolvaptan effectively increased urine output, reduced body weight, and relieved symptoms in two patients with severe congestive heart failure refractory to conventional diuretics.
Case Report (n=2)
Does tolvaptan improve fluid balance and symptoms in heart failure patients with fluid overload refractory to conventional diuretic therapies?
Tolvaptan is a potentially useful and safe short-term treatment for heart failure patients with fluid overload who are refractory to conventional intravenous and oral diuretic therapies.
While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.
Semba et al. (Sun,) conducted a case report in Congestive heart failure with fluid overload (n=2). Tolvaptan was evaluated on Relief of symptoms and fluid balance (urine volume, body weight). Tolvaptan effectively increased urine output, reduced body weight, and relieved symptoms in two patients with severe congestive heart failure refractory to conventional diuretics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: